Skip to main content
. 2023 Nov 20;2023(11):CD010966. doi: 10.1002/14651858.CD010966.pub4

36.2. Analysis.

36.2

Comparison 36: VX‐152 (300 mg twice daily) plus tezacaftor (100 mg once daily) plus ivacaftor (150 mg twice daily) versus placebo plus tezacaftor (100 mg once daily) plus ivacaftor (150 mg twice daily), Outcome 2: FEV1 % predicted (relative change from baseline)